European MS Platform

Advocacy and expertise for over 1 million people living with #MultipleSclerosis, NMOSD and MOGAD in Europe.

[European MS Platform @eumsplatform]

Welcome to the team, Delphine Sartiaux — our new Fundraising & Development Manager!
Delphine brings rich experience in fundraising, strategic partnerships & international stakeholder engagement across global health NGOs.
Delighted to have her on board 👋

[European MS Platform @eumsplatform]

On #WorldMSDay, our President Jan Van Amstel shares why today must be a day of purpose.
In MS, time lost too often means function lost. Diagnosis is only the start; timely access must follow.▶️ Watch below 🧡
@MSIntFederation @Lili_Bxl @annarevillab @eumsyouth

[European MS Platform @eumsplatform]

Progress on a new MS therapy — shaped by the people it's for.
At IMMUTOL's 3rd Annual Meeting in Siena 🇮🇹, EMSP brought expert patients Rebecca Maguire & @annarevillab into the room as the consortium advanced its vitamin D3 dendritic cell therapy for MS. #Immutol

[European MS Platform @eumsplatform]

Two days. 120+ participants. One shared conversation.
#EMSP2026 brought patients and experts to the same table-sharing research, naming gaps, shaping policy.
Thanks to @Roche and @sanofi for helping bring it to life and to everyone who showed up.
See you in Portugal.☀️ #EMSP2027

[European MS Platform @eumsplatform]

📍 RiMS 2026 | 11–13 June | Prague
The leading European gathering on MS rehabilitation — from neuroplasticity to real-world outcomes that matter most for people with MS.

Highlight: "Coping with MS" panel, chaired by EMSP CEO @Lili_Bxl .
🔗 https://t.co/srGchY2fEW #RiMS2026

[European MS Platform @eumsplatform]

516 patients per nurse.
That's the average caseload uncovered by our survey of 108 MS nurses across 15 countries.
Clinical trials, psychological support and benefits advice routinely left undone
Systemic change is overdue #InternationalNursesDay
Learm more https://t.co/WTjPg6mlXX

[European MS Platform @eumsplatform]

1.2M people live with MS in Europe and access to treatment still depends on where you live.
This May, our members @DMSG_BV 🇩🇪 & @MSIRELAND 🇮🇪 are taking on #TheMay50K, led by @MSIntFederation
Every kilometre moves research and equity forward.
Register- https://t.co/DwgRXrz3fI

[European MS Platform @eumsplatform]

@EUBrainFdn @EU_Commission @EUPHActs @Lili_Bxl Survey findings and reccomendations-https://t.co/iL1HfM2Yyc

[European MS Platform @eumsplatform]

1/ Final day of European Public Health Week 🇪🇺 — today's theme: the healthcare workforce.
Specialised MS nurses are the backbone of modern MS care. Without them, no therapy reaches its full potential. 🧵

[European MS Platform @eumsplatform]

5/ Investing in MS nurses = investing in the lives of people with MS.
📄 Full survey & recommendations:
#EUPHW #HealthcareWorkforce @EUBrainFdn @EU_Commission @EUPHActs @Lili_Bxl

[European MS Platform @eumsplatform]

@annarevillab @eumsyouth Survey findings and reccomendations- https://t.co/iL1HfM2Yyc

[European MS Platform @eumsplatform]

4/ 👉 Explore the Learning Corner: https://t.co/UGYNcEexa1

[European MS Platform @eumsplatform]

1/ It's European Public Health Week 🇪🇺 — today's theme: disinformation.
For people living with MS, NMOSD, and MOGAD, sorting fact from fiction online is a daily challenge. Misinformation isn't just confusing — it can be harmful. 🧵
#EUPHW

[European MS Platform @eumsplatform]

3/ Curated by EMSP and our partners. Evidence-based. Updated regularly as our projects progress.

[ECTRIMS @ECTRIMS]

🔍 𝐖𝐡𝐚𝐭 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐫𝐞𝐦𝐚𝐢𝐧 𝐢𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐧𝐠 𝐌𝐎𝐆𝐀𝐃? Our latest Spotlight, 𝘔𝘖𝘎𝘈𝘋: 𝘌𝘮𝘦𝘳𝘨𝘪𝘯𝘨 𝘐𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘌𝘷𝘰𝘭𝘷𝘪𝘯𝘨 𝘊𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴, explores the latest developments in MOGAD diagnosis, biomarkers, and therapeutic approaches.

Read the Spotlight here: https://t.co/OwPvVqNhSi

"While the criteria are a big step forward, obstacles remain in differentiating MOGAD from MS, which is crucial given the differences in treatment," says Professor Anne-Katrin Pröbstel of Universitätsklinikum Bonn and Universitätsspital Basel (USB).

"A key unresolved question in MOGAD management is: how long do we treat people for, both after an initial attack and in those who experience relapses?" adds Dr. Wei Yeh of Monash University in Melbourne.

The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania de Vito.

#MultipleSclerosis #MOGAD #MSResearch #Neurology #MSSpotlight #Neuroimmunology #ECTRIMS